BEAM incurs a narrower-than-expected loss in the fourth quarter. The company remains focused on pipeline development.

Full Year 2024 Results Key Financial Results Revenue: US$63.5m (down 83% from ...

In a report released today, Gena Wang from Barclays maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price target ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report)’s share price gapped up before the market opened on Tuesday following a stronger than expected earnings report. The stock had previously closed ...

In a report released yesterday, Luca Issi from RBC Capital maintained a Hold rating on Beam Therapeutics (BEAM – Research Report), with a price ...

While radiation therapy has been in use for more than 100 years, innovations including linear accelerators, imaging, and AI ...

Floating in the Rio Negro river in the Brazilian Amazon, Luiz Felipe, who has Down Syndrome, beams as he hugs a pink dolphin ...

BRAVE Holly Worswick thought her recurrent headaches were from not drinking enough water. But after she claims her GP blamed ...

The presentation will be available on IBA's investor relations website and on ...

Madrigal Pharmaceuticals MDGL reported fourth-quarter 2024 loss of $2.71 per share, narrower than the Zacks Consensus ...

One of the youngest victims of proposed NIH funding cuts would be six-year-old Cailen Vela of Michigan, who has a rare and ...